12:01 PM EST - Acerus Pharmaceuticals Corporation : Reported its financial results for the year ended December 31, 2019. Unless otherwise noted, all amounts are in U.S. dollars. Total revenue for 2019 was $3.8 million, compared to $7.4 million in the prior-year. Gross margin was $1.6 million compared with a negative gross margin of $2.9 million in 2018. The Company incurred a 2019 net loss of $16.1 million or $(0.06) per share compared to $18.8 million or $(0.08) for the same prior year periods. Acerus Pharmaceuticals Corporation
shares T.ASP are trading unchanged at $0.06.
